IDO1 and cervical cancer: In conclusion, the kyn/trp ratio in serum and IDO1 mRNA and protein expression per se in PTs cannot be used as a clear-cut biomarker for prognosis or to identify early stage cervical cancer patients eligible for clinical trials targeting IDO.